Neumora Therapeutics Financials - Benzinga

Neumora Therapeutics Inc

NMRANASDAQ

Trade with Public

Trade with Public

$1.31

-0.04-2.96%

At close: Sep 4, 5:00 PM EST

$1.31

N/A

After Hours: Sep 4, 7:01 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Neumora Therapeutics Financials

Neumora Therapeutics (NMRA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimate

Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 30.3 percent increase over losses of $(0.33) per share

Benzinga Newsdesk

PRO
Neumora Therapeutics Q1 EPS $(0.30) Beats $(0.33) Estimate

Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 28.57 percent increase over losses of $(0.42) per share

Benzinga Newsdesk

PRO
Neumora Therapeutics Q4 EPS $(0.35) Misses $(0.33) Estimate

Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 7.36 percent. This is a 5.41 percent increase over losses of $(0.37) per share

Benzinga Newsdesk

Earnings Scheduled For March 30, 2026

Benzinga Insights

PRO
Neumora Therapeutics Q3 EPS $(0.35) Misses $(0.33) Estimate

Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 4.79 percent. This is a 22.22 percent increase over losses of $(0.45) per share

Benzinga Newsdesk

PRO
Neumora Therapeutics Q2 EPS $(0.33) Beats $(0.37) Estimate, $217.6M In Cash, Cash Equivalents And Marketable Securities Expected To Support Operations Into 2027

Benzinga Newsdesk